A 66-kDa glycosylated carboxypeptidase, plasma procarboxypeptidase B (pro-plasma CPB), has recently been identified in human blood (Eaton, D. L., Malloy, B. E., Tsai, S. P., Henzel, W., and Drayna, D. (1991) J. Biol. Chem. 266, 21833-21838). The pro-enzyme binds to plasminogen and the active enzyme is specific for COOHterminal Lys or Arg residues. These properties implicate a role in the fibrinolytic or coagulation system. However, we show that the molecular mass of the active plasma CPB is approximately 36 kDa, which is below the glomerular filtration limit. Since activated plasma CPB no longer binds plasminogen, the active enzyme may not be retained in the circulation. To investigate this, we performed plasma elimination studies in mice which showed that 125 I-plasma CPB remains in the circulation despite its small size. Native polyacrylamide gel electrophoresis of blood samples removed from the mice revealed that plasma CPB migrated as a high molecular weight band. Similar bands were observed in vitro when 125 I-plasma CPB was added to plasma from humans and other species. The plasma CPB-binding proteins were purified from human plasma and identified as ␣ 2 -macroglobulin (␣ 2 M) and pregnancy zone protein. Only the active enzyme bound to the two ␣-macroglobulins, and the interaction was specific for ␣ 2 M in its native conformation, but not its receptor recognized forms. The complex between human ␣ 2 M and plasma CPB dissociated during SDS-polyacrylamide gel electrophoresis and transverse urea gel electrophoresis suggesting that the interaction was noncovalent and depended on the tertiary structure of the native ␣ 2 M molecule. The catalytic activity of plasma CPB was not significantly affected by its binding to ␣ 2 M. The specific binding of plasma CPB to ␣-macroglobulins suggest that these proteins may function as a "shuttle" in vivo to modulate the clearance of plasma CPB from the circulatory system.
I-plasma CPB remains in the circulation despite its small size. Native polyacrylamide gel electrophoresis of blood samples removed from the mice revealed that plasma CPB migrated as a high molecular weight band. Similar bands were observed in vitro when 125 I-plasma CPB was added to plasma from humans and other species. The plasma CPB-binding proteins were purified from human plasma and identified as ␣ 2 -macroglobulin (␣ 2 M) and pregnancy zone protein. Only the active enzyme bound to the two ␣-macroglobulins, and the interaction was specific for ␣ 2 M in its native conformation, but not its receptor recognized forms. The complex between human ␣ 2 M and plasma CPB dissociated during SDS-polyacrylamide gel electrophoresis and transverse urea gel electrophoresis suggesting that the interaction was noncovalent and depended on the tertiary structure of the native ␣ 2 M molecule. The catalytic activity of plasma CPB was not significantly affected by its binding to ␣ 2 M. The specific binding of plasma CPB to ␣-macroglobulins suggest that these proteins may function as a "shuttle" in vivo to modulate the clearance of plasma CPB from the circulatory system.
Until recently it was assumed that the only plasma carboxypeptidase capable of releasing COOH-terminal Arg and Lys residues was carboxypeptidase N (Plummer and Erdos, 1981; Skidgel, 1995) . This enzyme has been implicated in modulating the properties and activities of several peptide hormones and proteins, including kinins, anaphylatoxins, fibrinopetides, enkephalin hexapeptides, and creatine kinase (Skidgel, 1988; Tan et al., 1990) . However, a novel plasma pro-carboxypeptidase B (pro-plasma CPB), 1 with similar specificity was recently isolated from plasma by plasminogen Sepharose affinity chromatography (Eaton et al., 1991) . The protein sequence predicted from cDNA revealed that the protein is structurally similar to pancreatic pro-carboxypeptidase B (Eaton et al., 1991) . The gene encoding pro-plasma CPB resides on chromosome 13 (Tsai and Drayna, 1992 ) and the protein is secreted by the liver.
Activation of pro-plasma CPB may be achieved by proteolysis of the Arg 92 -Ala 93 peptide bond by trypsin or other Arg-specific serine proteinases. However, the activation of pro-plasma CPB requires high concentrations of these proteinases and results in concomitant inactivation (Eaton et al., 1991; Tan and Eaton, 1995; Bajzar et al., 1995) . This is in contrast to the homologous pancreatic pro-carboxypeptidase B, which is activated by relatively low concentrations of trypsin and suffers no further degradation (Reeck and Neurath, 1972; Burgos et al., 1991) . Unlike pancreatic pro-carboxypeptidase B whose function is to serve as a digestive enzyme, the function of pro-plasma CPB is unclear, although its interaction with plasminogen suggests a role in fibrinolysis.
The binding of pro-plasma CPB to plasminogen is mediated by the plasminogen Lys binding sites. These Lys binding sites are also important for the activation and regulation of plasminogen (Lijnen et al., 1980; Clemmensen, et al., 1981 Clemmensen, et al., , 1986 Pannell et al., 1988; Miles et al., 1991; Lenich et al., 1991) . Specifically, the binding of ␣ 2 -antiplasmin to plasminogen have been shown to depend on Lys residues present in the COOHterminal region of ␣ 2 -antiplasmin (Sasaki et al., 1986; Hortin et al., 1988) . In addition, the Lys binding sites participate in the binding of plasminogen and plasmin to fibrin and fibrinogen. A newly formed fibrin clot does not contain any COOH-terminal Lys residues and the plasminogen and the plasmin binding capacity is limited. Following the initial partial plasmin degradation COOH-terminal Lys residues are exposed and these residues act as additional binding sites for tissue plasminogen activator, plasminogen, and plasmin. The exposure of these Lys residues most likely affects the stamina of the fibrin clot (Tran-Tang et al., 1986; Higgins and Vehar, 1987) . Consequently, the interaction between Lys and Lys binding sites represents a potential target for regulation of the fibrinolytic system. In particular, it has been suggested that the binding of histidine-rich glycoprotein to the Lys binding sites of plasminogen may prevent the binding of plasminogen to fibrinogen and fibrin (Lijnen et al., 1980; Ichinose et al., 1984) . It is similarly conceivable that a Lys-specific carboxypeptidase may interfere with the degradation of the fibrin clot by removing COOH-terminal Lys residues from fibrin (Pannell et al., 1988; Miles et al., 1991; Bajzar et al., 1995) .
Any potential biological role for plasma CPB is limited by the biodistribution of the active enzyme. Since the 36-kDa plasma CPB is smaller than the glomerular filtration limit of approximately 60 kDa, it may be expected that plasma CPB is quickly removed from the blood stream. However, we have found that the active enzyme is retained in the circulation of mice. In addition we describe the strong interactions between plasma CPB and the ␣-macroglobulin proteinase inhibitors ␣ 2 -macroglobulin (␣ 2 M) and pregnancy zone protein in terms of binding specificity, stability of the interaction, and effect on the proteolytic activity of plasma CPB. The interaction with these large proteins could prevent the renal filtration of plasma CPB and explain its slow clearance from the bloodstream. Thus, the interaction of plasma CPB with the ␣-macroglobulins may modulate its biodistribution and capacity to hydrolyze substrates in the fibrinolytic system.
EXPERIMENTAL PROCEDURES
Materials-3,4-Dichloroisocoumarin, phenylmethylsulfonyl fluoride, and bovine trypsin were from Sigma. The chromogenic substrates for trypsin (H-D-Pro-Phe-Arg-p-nitroanilide) and for plasma CPB (FA-AlaArg-OH) were obtained from Helena Laboratories, Beaumont, TX, and BACHEM Bioscience Inc., Switzerland. Lactoperoxidase-glucose oxidase and electrophoresis reagents were from Bio-Rad. Ultrapure urea was obtained from Life Technologies, Inc. Na[ l25 I] (17.4 Ci/mmol) was from DuPont NEN. Pro-plasma CPB antiserum was raised commercially (Pel-freez, Rogers, AR). Fresh frozen human plasma was obtained from American Red Cross Blood Services, Charlotte, NC.
Protein Purification-Pro-plasma CPB and ␣ 2 -antiplasmin were purified from human plasma by plasminogen-Sepharose affinity chromatography as described previously (Wiman, 1980; Eaton et al., 1991) . Pro-plasma CPB was separated from ␣ 2 -antiplasmin by anion exchange chromatography on a Mono-Q HR 5/5 column (Pharmacia) connected to a Pharmacia FPLC system. The column was equilibrated in 50 mM Tris-Cl, pH 7.4 (buffer A), and developed using a 0.3%/min linear gradient from buffer A to 50 mM Tris-Cl, pH 7.4, containing 1 M NaCl (buffer B) at a flow rate of 1 ml/min. Plasminogen (Deutsch and Mertz, 1970) and ␣ 2 M (Salvesen and Enghild, 1993) were purified as described previously. Anhydrotrypsin was prepared as described by Sayers and Barrett (1980) .
Identification and Purification of Plasma CPB-binding Proteins in Human
Plasma-To identify the plasma CPB-binding proteins, human plasma was fractionated as described below. The fractions containing the plasma CPB-binding proteins were identified by incubating 125 Iplasma CPB and the sample of interest followed by native PAGE and autoradiography. All purification steps were performed at 4°C. One liter of human plasma was made 5% in polyethylene glycol 8000. The pellet was collected by centrifugation and discharged. Additional polyethylene glycol 8000 was added to a final concentration of 25%. The pellet was collected, dissolved in 50 mM Tris-Cl, pH 7.4, and dialyzed extensively against water. The dialysate was cleared by centrifugation and 2 M Tris-Cl, pH 7.4, buffer was added to a final concentration of 50 mM. The sample was further fractionated by dye ligand chromatography using a 5 ϫ 30-cm Cibachrone Blue-Sepharose CL-4B column (Pharmacia). The column was equilibrated in 50 mM Tris-Cl, pH 7.4, and the sample was applied at a flow rate of 1.5 ml/min. The flowthrough was collected in 5-ml fractions and assayed for plasma CPB binding activity as described above. The active fractions were applied to a 2.5 ϫ 30-cm DEAE Sephacel column (Pharmacia) equilibrated in 50 mM Tris-Cl, pH 7.4 (buffer A). The column was developed using a flow rate of 0.5 ml/min and a linear gradient composed of 500 ml of 50 mM Tris-Cl, pH 7.4 (buffer A), and 500 ml of 50 mM Tris-Cl, pH 7.4, containing 400 mM NaCl (buffer B). Fractions containing the plasma CPB-binding proteins were pooled and concentrated by ultrafiltration using a Amicon YM10 filter and a Amicon ultrafiltration apparatus. Following concentration, the sample was separated by size exclusion chromatography using a 2.5 ϫ 170-cm Sephacryl S300 HR column (Pharmacia), equilibrated in 50 mM Tris-Cl, 100 mM NaCl, pH 7.4. The final purification was achieved using a Mono Q 5/5 HR column (Pharmacia) connected to a Pharmacia FPLC system. The column was equilibrated in 50 mM Tris-Cl, pH 7.4 (buffer A), and developed using a linear gradient of 1%/min of 50 mM Tris-Cl, pH 7.4, containing 1 M NaCl (buffer B) at a flow rate of 1 ml/min.
SDS-Polyacrylamide Gel
Electrophoresis-Samples were boiled in SDS sample buffer in the presence of 50 mM dithiothreitol. SDS-PAGE was performed in 5-15% gradient gels (10 ϫ 10 ϫ 0.15 cm) using the glycine, 2-amino-2-methyl-1,3-propanediol, HCl system described by Bury (1981) .
Nondenaturing Polyacrylamide Gel Electrophoresis-The proteins were analyzed in the same system as described for SDS-PAGE except that SDS was omitted from all buffers, and samples were not boiled or treated with 50 mM dithiothreitol. Some samples were analyzed by pore limit gel electrophoresis as described previously (Manwell, 1977) .
Transverse Urea Gradient (TUG) Polyacrylamide Gels-The 5% polyacrylamide TUG gels contained a continuous 0 -8 M urea gradient in the gel buffer system described above (Goldenberg, 1989; Mast et al., 1991) . The gels were cast in batches of 9 (10 ϫ 9 ϫ 0.15 cm), rotated 90°, and samples of 75-100 g of protein were loaded evenly across the top of the gel. Electrophoresis was performed at 23°C with a constant current of 13 mA for 5 h. Proteins were visualized by staining with Coomassie Blue or autoradiography.
Radiolabeling of Proteins-Plasma CPB was radioiodinated employing the chloramine-T method (Hunter and Greenwood, 1962) . Approximately 0.5 mg of protein was labeled using 1 mCi of 125 I followed by desalting on a PD-10 column (Pharmacia).
Plasma Elimination Studies-This procedure has been described in detail elsewhere (Imber and Pizzo, 1981) . In brief, approximately 0.25 g of protein equivalent to 10 6 cpm of radioiodinated pro-plasma CPB or plasma CPB were injected into the lateral tail vein of CD-1 mice. Blood samples of 25 l were collected at timed intervals via retro-orbital puncture. The initial time point, taken 10 -15 s after injection, was considered to represent 100% radioactivity in the circulation. Each clearance experiment was performed at least 3 times and the results were averaged.
Amino Acid Sequence Analysis-Automated Edman degradation was carried out in an Applied Biosystems 477A sequencer with on-line analysis of the phenylthiohydantoins using an Applied Biosystems 120A HPLC. Some samples were transferred to polyvinylidene difluoride membranes before Edman degradation either by electroblotting (Matsudaira, 1987) or using pro-spin sample preparation cartridges (Applied Biosystems).
Amino Acid Analysis-The concentrations of proteins were determined by amino acid analysis. The samples were desalted and the absorbance at 280 and 230 nm were determined. Aliquots were dried, hydrolyzed for 24 h in 6 M HCl, and applied to a Beckman 6300 amino acid analyzer.
Tryptic Activation of Pro-plasma CPB-The activation of pro-plasma CPB was followed by enzyme kinetics and SDS-PAGE. Activation was carried out at a known zymogen concentration as determined by the A 280 , in 50 mM Hepes, 100 mM NaCl, pH 7.4. The activation was examined by titrating a fixed concentration of pro-plasma CPB with increasing amounts of trypsin. For kinetic characterization of the activation, an aliquot of the activated sample corresponding to an initial zymogen amount of 3.5 g was used in a standard assay (described below), thus following trypsin dependent changes in catalytic activity. The ratio of pro-plasma CPB/plasma CPB formed during the activation was estimated by SDS-PAGE of trypsin-activated 125 I-pro-plasma CPB. The gels were dried and subjected to imaging on a PhosphorImager 410A (Molecular Dymamics, Sunnyvale, CA). The size of pro-plasma CPB and plasma CPB was estimated on a calibrated Spherogel TSK 3000 PWHR size-exclusion HPLC column (Beckman) as described previously (Enghild et al., 1994) .
Competitive Radioimmunoassays-To investigate the specificity of the interaction between activated plasma CPB and ␣ 2 M, competition studies for the binding of 125 I-plasma CPB to native ␣ 2 M were performed using excesses of pro-plasma CPB, plasma CPB, and anhydrotrypsin. Microtiter plates, 96 wells, were coated with ␣ 2 M antiserum in 100 l of 50 mM HEPES, 100 mM NaCl, pH 7.4, and incubated for 24 h at 4°C. The wells were washed once with 200 l of 50 mM HEPES, 100 mM NaCl, pH 7.4, and three times with the same buffer containing 1% bovine serum albumin (radioimmunoassay buffer). To block residual binding sites, a 2-h incubation in radioimmunoassay buffer was performed during the second wash. Native ␣ 2 M (10 pmol at a concentration of 100 nM) was added to the antiserum-coated wells and allowed to bind for 2 h at 23°C. Incubation media was prepared by mixing increasing concentrations of unlabeled competing ligand with 5 nM l25 I-plasma CPB in radioimmunoassay buffer. Aliquots of incubation media were added to the wells in a final volume of 100 l. Following a 3-h incubation the wells were washed with 3 ϫ 200 l of radioimmunoassay buffer, removed, and counted for ␥-radioactivity. All experiments were performed in duplicate and the results averaged.
Estimation of Binding Affinity-The data for the displacement of 125 I-plasma CPB by plasma CPB was analyzed by using the equilibrium binding data analysis module of the software Radlig®, version 4 (Biosoft, Ferguson, MO). Since the activation peptide only contained 1 out of a total of 24 Tyr residues (Eaton et al., 1991) , the active 36-kDa fragment was assumed to contain all the radioactivity. Under the activation conditions used, approximately 48% of the pro-plasma CPB was activated. This activation ratio was utilized in the calculations since the data from competitive radioimmunoassays and from analysis of fractions separated by size exclusion chromatography showed that only active plasma CPB binds to ␣ 2 M (see "Results").
Determination of Plasma CPB Activity-The activity of plasma CPB was determined essentially as described by Hendriks et al. (1985) . Tubes containing 10 l of sample were incubated with 40 l of 30 mM hippuryl-Arg in 50 mM HEPES, 0.1% Nonidet P-40, pH 8.0, at 37°C. The reactions were stopped at different times by adding 50 l of 1 M HCl. Ten l of a 15 mM ortho-methylhippuric acid was added as internal standard. The internal standard and the product hippuric acid were extracted with 300 l of ethyl acetate and separated by RP-HPLC. Aliquots of 100 l were dried and dissolved in 200 l of 10 mM KH 2 PO 4 , pH 3.5, containing 15% acetonitrile. Aliquots of 10 l were analyzed by reverse phase-HPLC on a Waters 3.9 ϫ 150-mm Bondapak C18 column in the same buffer connected to a Beckman 126/166 HPLC system. The data was collected on an IBM PS2 computer and analyzed using the Beckman System Gold chromatography software. Product and internal standard were detected at 228 nm, and the amount estimated based on a calibration curve.
Plasma CPB (1 g) was incubated with 26 g of ␣ 2 M, ␣ 2 M-methylamine (␣ 2 M-MA), ␣ 2 M-trypsin, and reduced and alkylated ␣ 2 M in 50 mM HEPES, 0.1% Nonidet P-40, pH 8.0, for 30 min at 23°C. The resulting plasma CPB activity was then determined as described above.
RESULTS
Tryptic Activation of Pro-plasma CPB-Plasma CPB is unstable to trypsin and is inactivated by cleavage of Arg 330 -Tyr 33l requiring a careful optimization of the activation conditions (Eaton et al., 1991; Tan and Eaton, 1995) . The activation of pro-plasma CPB was monitored by both enzyme kinetics and SDS-PAGE (Fig. 1) . The activation efficiency did not permit the use of low trypsin to pro-plasma CPB ratios to control the reaction. The optimal activation, based on kinetic studies was obtained with ratios of trypsin to pro-plasma CPB of 0.8:1 for 20 min at 23°C. Under these conditions 48% of the pro-plasma CPB was activated based on electrophoretic shift of radiolabeled enzyme. Analysis of the activation reaction by SDS-PAGE revealed several products (Fig. 1) . Edman degradation of the 36-kDa plasma CPB band identified two sequences in a 1:1 ratio. The expected Arg 92 -Ala 93 trypsin activation cleavage site in plasma CPB and the NH 2 -terminal sequence of pro-plasma CPB. Although the apparent molecular mass of the glycosylated NH 2 -terminal activation peptide is only approximately 20 kDa, it appears to comigrate with the 36-kDa plasma CPB (Fig.  1) . This can be explained by the observation that glycosylated peptides often exhibit aberrant behavior during SDS-PAGE. It is also possible that the presence of the NH 2 -terminal fragment is the result of an unidentified COOH-terminal trypsin cleavage of pro-plasma CPB. This appears less likely, as we did not observe this hypothetical COOH-terminal fragment or a 20-kDa activation peptide in the gels.
Plasma Elimination Kinetics of Pro-plasma CPB and Trypsin-activated Plasma CPB-Both

125
I-pro-plasma CPB and trypsin-activated 125 I-plasma CPB remained in the circulation of the mouse with a half-life of several hours (Fig. 2) . The trypsin activated 125 I-plasma CPB (including activation peptide and degradation products) were removed slightly faster than 125 I-pro-plasma CPB. This slightly accelerated clearance could be due to glomerular filtration of the activation peptide and the degradation products described above. However, despite its small size, the 36-kDa 125 I-plasma CPB remained in the circulation with a half-life of several hours, suggesting that l25 I-plasma CPB interacts with components in the blood. Native PAGE analysis of the blood samples removed from the mice supported this notion as high molecular weight bands were apparent (data not shown). In the figure proplasma CPB and plasma CPB were abbreviated to pro-pCPB and pCPB, respectively. Panel A, pro-plasma CPB was incubated with increasing molar ratios of trypsin as indicated for 20 min at 37°C. The reactions were terminated by the addition of 3,4-dichloroisocoumarin and the samples were analyzed by reduced SDS-PAGE. The activity of each sample was determined using the substrate hippuryl-Arg as described under "Experimental Procedures." The best activation was achieved at trypsin:pro-plasma CPB molar ratio of 0.8:1. Panel B, the trypsin activation of pro-plasma CPB generated several fragments. These fragments were identified by Edman degradation following transfer to polyvinylidene difluoride membranes. The schematic shows the location of the trypsin cleavage sites within the primary structure of pro-plasma CPB. The glycosylation of the activation peptide is indicated (ࡗ). I-proplasma CPB or 125 I-plasma CPB were injected into the lateral tail vein of a mouse as described under "Experimental Procedures." Blood samples were removed by retro-orbital puncture at the indicated time points. Pro-plasma CPB is represented by q and trypsin activated plasma CPB by E. The clearance rates of the zymogen and the active enzyme are essentially the same.
Components in Mammalian Plasma
analyzed by native PAGE and autoradiography. We did not observe the complex between pro-plasma CPB and plasminogen in native PAGE most likely because: (i) the complex dissociated during native PAGE or (ii) the isoelectric point of the complex is higher than the pH of the buffer system, pH 8.5, preventing the then positively charged complex from entering the gel. Interestingly, when plasma was incubated with 125 Iplasma CPB and examined by native PAGE, we observed high molecular weight bands similar to those seen in the in vivo mouse plasma clearance experiments described above. This suggests that 125 I-plasma CPB was bound to proteins in the plasma (Fig. 3) . These bands were also seen when 125 I-plasma CPB was incubated with plasma from species other than humans and mice suggesting the presence of orthologous proteins in the blood of these species (Fig. 3) . Incubation of plasma with 125 I-pro-plasma CPB did not result in high molecular weight forms of 125 I-pro-plasma CPB, implying that the interaction is specific for plasma CPB. We proceeded to purify the plasma CPB-binding proteins present in human plasma.
Purification and Identification of the Plasma CPB-binding Proteins from Human Plasma-
The plasma CPB-binding proteins identified in plasma were purified to homogeneity by a combination of polyethylene glycol precipitation and column chromatography. The purified proteins were analyzed by Edman degradation and 20 amino acid residues from the NH 2 -terminal of each protein were identified. The obtained protein sequence data were used in a computer assisted homology search in the National Biomedical Research Foundation (NBRF) Protein Identification Resources (PIR) data base, release number 44. A complete match for both proteins was obtained identifying the proteins as human ␣ 2 M (SottrupJensen et al., 1984) and human pregnancy zone protein (Devriendt et al., 1991) . In contrast to pregnancy zone protein, human ␣ 2 M is found in high concentration in normal plasma. We therefore, used ␣ 2 M as a model for examining the interaction between plasma CPB and ␣-macroglobulins.
Binding of Plasma CPB to Native ␣ 2 M, Proteinase Complexed ␣ 2 M, or ␣ 2 M-MA-The ability of pro-plasma CPB and plasma CPB to bind native ␣ 2 M, trypsin-treated ␣ 2 M, or ␣ 2 Mmethyl amine was investigated (Fig. 4) . Because ␣ 2 M may exist either in its native confirmation, which is stable in plasma or a receptor-recognized confirmation which is cleared rapidly, binding of plasma CPB to these conformational forms were examined. The two conformational forms have been denoted slow, and fast based on the migration in native PAGE (Barrett and Starkey, 1973) . Samples of each conformational form of ␣ 2 M were incubated with 125 I-pro-plasma CPB or 125 I-plasma CPB and analyzed by native PAGE. Pro-plasma CPB did not bind to any of the ␣ 2 M species (not shown). However, plasma CPB bound strongly to native ␣ 2 M but only weak binding was observed with faster migrating conformations (␣ 2 M-methyl amine and ␣ 2 M-trypsin). The interaction between plasma CPB and ␣ 2 M was further investigated by a microtiter binding assay.
The Interaction between the Pro-plasma CPB Trypsin Activation Product and ␣ 2 M Are Specific for plasma CPB-Trypsin activation of pro-plasma CPB resulted in several reaction products as described above. Experiments were performed to determine which of these protein species bound to ␣ 2 M.
125
I-Proplasma CPB was activated with trypsin as described under "Experimental Procedures." Residual trypsin activity was removed by soybean trypsin inhibitor-Sepharose affinity chromatography before the trypsin activated 125 I-pro-plasma CPB reaction products were incubated with ␣ 2 M for 30 min at 23°C. The components of the incubation mixture were separated by size exclusion chromatography on a Superose 6 column connected to a Pharmacia FPLC system (Fig. 5A) . The radioactive fractions were pooled and analyzed by SDS-PAGE and autoradiography (Fig. 5B) . The ␣ 2 M containing pool was treated with methylamine, prior to SDS-PAGE, in order to cleave the ␣ 2 M thiol ester. This was done to prevent denaturation induced activation of the thiol ester and subsequent thiol ester-mediated covalent binding of 125 I-plasma CPB as an artifact of SDS-PAGE. Examination of the ␣ 2 M containing fractions (peak 1) by SDS-PAGE and autoradiography (Fig. 5B) revealed only one band. The position of this band was identical to the position of the 125 I-plasma CPB control. We conclude from these data that the binding of the trypsin activation pro-plasma CPB products to ␣ 2 M was specific for plasma CPB.
Equilibrium Displacement Assays-We performed competitive radioimmunoassays assessing the effects of unlabeled competing ligands, pro-plasma CPB, plasma CPB, or anhydrotryp- I-plasma CPB was added to 100 l of plasma from different animal species as indicated. Twenty five l of the samples were analyzed after a short incubation by pore limit gel electrophoresis. In parallel experiments using 125 I-pro-plasma CPB, we did not detect binding to other plasma proteins (data not shown). In contrast, trypsin activated plasma CPB bound to high molecular weight protein(s) present in the plasma. The position for tetrameric (725 kDa), dimeric (360 kDa), and monomeric (180 kDa (Fig. 6) . Only plasma CPB competed with the binding of the 125 I-plasma CPB, suggesting that the interaction was specific. Analysis of this cold saturation equilibrium binding data yielded a K d in the 2-3 mM range. Pro-plasma CPB was unable to compete for binding to ␣ 2 M even at a 1000-fold molar excess confirming that the pro-plasma CPB component does not bind to ␣ 2 M. Similarly, no competition was observed using anhydrotrypsin as the competing ligand. Since it is known that anhydrotrypsin binds to ␣ 2 M (Sayers and Barrett, et al., 1980) , the data suggest that plasma CPB and anhydrotrypsin bind to different sites on the ␣ 2 M molecule.
␣ 2 M-Plasma CPB Binding Stochiometry-The binding of plasma CPB to ␣ 2 M was investigated by incubating known concentrations of ␣ 2 M with 125 I-plasma CPB. The resulting ␣ 2 M⅐ 125 I-plasma CPB complex was purified by native PAGE and the dried gel was subjected to imaging on a PhosphorImager 410A and Densitometer 300S (Molecular Dymamics). These experiments suggested that 1 mol of ␣ 2 M bound 2 mol of plasma CPB (data not shown).
Thermodynamic Stability of the Complex between plasma CPB and ␣ 2 M-
125
I-Pro-plasma CPB was activated with trypsin before incubation with ␣ 2 M or ␣ 2 M-methyl amine as described under "Experimental Procedures." The samples were analyzed by TUG gel electrophoresis and autoradiography (Fig.  7) . The complex between ␣ 2 M⅐ 125 I-plasma CPB dissociated at approximately 2 M urea. This confirms the strong but noncovalent nature of the interaction. Dissociation of the ␣ 2 M⅐plasma CPB complex appears to coincide with the disruption of the tertiary structure of ␣ 2 M (Fig. 7B) .
The Binding of Plasma CPB to ␣-Macroglobulins Did Not Affect the Carboxypeptidase Activity-To study if the plasma CPB activity was affected by the binding to ␣ 2 M we compared the rates of substrate hydrolysis of free plasma CPB with that of plasma CPB in the presence of ␣ 2 M, ␣ 2 M-MA, or reduced and alkylated ␣ 2 M (Fig. 8) . The change in the rate of substrate hydrolysis following preincubation with ␣ 2 M and the ␣ 2 M derivatives were insignificant. We conclude that the binding of plasma CPB to ␣ 2 M does not alter its activity.
DISCUSSION
The 60-kDa pro-plasma CPB most likely circulates in complex with plasminogen. This affinity for plasminogen is lost with proteolytic activation to plasma CPB (Tan and Eaton, 1995) . The activation peptide is glycosylated and contributes significantly to the size of pro-plasma CPB. Size exclusion chromatography of pro-plasma CPB and plasma CPB suggests FIG. 5 . Purification of ␣ 2 M-plasma CPB complex. Pro-plasma CPB and plasma CPB were abbreviated pro-pCPB and pCPB, respectively. Panel A, approximately 500 g of ␣ 2 M⅐ 125 I-plasma CPB complex was separated on a Superose 6 size exclusion column connected to a Pharmacia FPLC system. The column elute was monitored at a wavelength of 280 nm (-) and each fraction was counted for radioactivity (---). There was one absorbance peak (peak 1) representing ␣ 2 M, and three major radioactive peaks arising from trypsin treated pro-plasma CPB. Panel B, the purified complex was treated with methylamine and iodoacetic acid prior to SDS-PAGE to prevent denaturation induced thiol ester activation and subsequent formation of ⑀-lysyl-␥-glutamyl cross-links between 125 I-plasma CPB and ␣ 2 M. The peaks eluting from the column were analyzed by SDS-PAGE followed by autoradiography. Pro-plasma CPB and plasma CPB are shown for comparison. Apparently, ␣ 2 M specifically binds plasma CPB (peak 1) since the pro-plasma CPB which escaped trypsin activation eluted separately (peak 2). The third peak (peak 3) probably represent small fragments of pro-CPB generated during the trypsin activation (see Fig. 1 ).
FIG. 6. Equilibrium displacement assays.
The ligands pro-plasma CPB (E), plasma CPB (q), and anhydrotrypsin (ϫ) were allowed to compete with 125 I-plasma CPB (5 nM) for binding to immobilized native ␣ 2 M as described under "Experimental Procedures." 125 I-Plasma CPB and increasing amounts of the competing ligands were added concurrently to the wells. It is apparent that only plasma CPB competed for binding.
that the activation peptide dissociates following activation. Consequently, the 36-kDa plasma CPB would be expected to undergo elimination by glomerular filtration. This hypothesis was supported by the finding that the half-life of pancreatic carboxypeptidase B injected into the bloodstream is only a few minutes (Erdos et al., 1963) . If plasma CPB is eliminated from the blood as quickly as pancreatic carboxypeptidase B, it would be difficult to imagine a significant role for regulating biological processes within the circulatory system. However, using mouse plasma elimination studies, we found that both the zymogen and the enzymatically active 36-kDa plasma CPB remained in the blood. More importantly, our data indicate that plasma CPB is not eliminated by glomerular filtration because it binds to ␣ 2 M and pregnancy zone protein present in plasma. Human plasma CPB was able to form complexes with similar high molecular weight proteins present in the plasma of other mammalian species, birds, and even amphibians, suggesting evolutionary conservation of the binding mechanism.
The involvement of the ␣-macroglobulins is interesting since, besides functioning as proteinase inhibitors, more recent evidence suggests that ␣ 2 M may regulate the plasma stability or clearance of various smaller proteins such as hormones, growth factors, cytokines, and antigens (LaMarre et al., 1991; Gonias, 1992; Borth, 1992; Chu and Pizzo, 1994) . In many cases, the actual mechanism(s) of binding have not been fully defined. We investigated the possible role of two well defined mechanisms of binding to ␣ 2 M. Following proteolytic cleavage of the ␣ 2 M "bait region," the thiol esters become highly reactive and may interact with amino groups on the surface of the attacking proteinase, or other proteins in the vicinity, to form covalent ⑀-lysyl-␥-glutamyl cross-links (reviewed in Chu and Pizzo (1994) ). Concurrently, ␣ 2 M undergoes a conformational change, migrating faster during native PAGE. This form of ␣ 2 M is recognized by cell surface receptors and is rapidly removed from the circulation (Imber and Pizzo, 1981) along with the bound proteins. Analysis of the ␣ 2 M⅐plasma CPB complex by native PAGE revealed that plasma CPB was bound exclusively to the slow form of ␣ 2 M and it did not elicit a conformational change, consistent with its slow clearance from the circulation. Moreover, there was no evidence for covalent crosslinks during analysis by SDS-PAGE. Thus, plasma CPB interacts with ␣ 2 M in a manner distinct from endoproteinases. Likewise, although anhydrotrypsin also interacts noncovalently with slow ␣ 2 M, binding to a site on the surface of ␣ 2 M distinct from that occupied by active proteinases, anhydrotrypsin, did not displace plasma CPB from ␣ 2 M. Thus, anhydrotrypsin and plasma CPB do not occupy the same site. Other properties of the plasma CPB binding site characterized in this study include the finding that: (i) the site is masked during the slow to fast conformational change, and (ii) the interaction depends on the native conformations of ␣ 2 M and plasma CPB since the complex dissociates during TUG electrophoresis.
Pro-plasma CPB can be activated in vitro by cleavage of Arg 92 -Ala 93 by Arg-specific proteinases including trypsin, thrombin, and plasmin (Eaton et al., 1991; Bajzar et al., 1995) . The activation requires high concentrations of proteinases, and all the proteinases examined so far concomitantly inactivate plasma CPB by cleaving the Arg 330 -Tyr 331 bond. Although it has been suggested that this inactivation may function as a control mechanism in vivo (Eaton et al., 1991) , the data in this study suggest an alternative scenario. Trypsin activation of pro-plasma CPB did indeed generate several products, including the activation peptide, a COOH-terminal peptide, active plasma CPB, and a NH 2 -and COOH-terminal truncated fragment (see Fig. 1 ). Size exclusion chromatography followed by SDS-PAGE demonstrated that the interaction between ␣ 2 M and the activation products was specific for intact plasma CPB (Fig. 5) . Moreover, it was only activated plasma CPB, and not pro-plasma CPB, that was bound (Figs. 3, 4 , and 6). It is, thus, likely that plasma CPB binds ␣ 2 M following activation and is protected from further degradation by either the activating proteinase or other proteinases. Of note is the fact that the interaction is specific for the conformational form of ␣ 2 M with a long plasma half-life, and this form is an efficient inhibitor of most endoproteinases (Salvesen and Enghild, 1993) . A high molecular weight carboxypeptidase has recently been identified in human plasma (Wang et al., 1994) . This enzyme called unstable carboxypeptidase (CPU) has a similar specificity and size as plasma CPB, and seems to be noncovalently associated with high molecular weight plasma proteins. It is conceivable that the detected activity is derived from the ␣ 2 M⅐plasma CPB complex and not a novel carboxypeptidase.
Since the binding of plasma CPB with ␣ 2 M did not affect its catalytic activity, this interaction represents a potentially important mechanism for prolonging the availability of the active enzyme. This finding is consistent with the proposed role of pro-plasma CPB in regulation of fibrinolysis, coagulation, and other COOH-terminal Lys dependent events.
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FIG. 8. Effect of ␣ 2 M on the activity of plasma CPB. The substrate hippuryl-Arg is hydrolyzed by plasma CPB. The resulting product hippuric acid and the remaining substrate were extracted and separated by reverse phase-HPLC. The amount of product was determined spectrophotometrically. Approximately 1 g of plasma CPB alone (E) or after a 30-min preincubation with 26 g of the following ␣ 2 M derivatives: ␣ 2 M (छ), ␣ 2 M-methyl amine (Ç), ␣ 2 M-trypsin (Ⅺ), and reduced and alkylated ␣ 2 M (ϫ). The samples were analyzed as a function of time. No significant differences in rate of substrate hydrolysis are observed.
